Table 1

Availability of review and investigations in IBD centres and their associated networks

Able to physically review new and known patients with IBDDo you have access to faecal calprotectin?Does your referring network calprotectin?Do you have access to ultrasound?Does your referring network ultrasound?Do you have access to MRI?Does your referring network MRI?
Not available1 site (5%)3 sites (15%)3 sites (15%)2 sites (10%)2 sites (10%)2 sites (10%)2 sites (10%)
Reduced compared with pre-COVID-1915 sites (75%)3 sites (15%)10 sites (50%)2 sites (10%)9 sites (45%)3 sites (15%)10 sites (50%)
No difference compared with pre-COVID-194 sites (20%)14 sites (70%)5 sites (25%)16 sites (80%)4 sites (20%)15 sites (75%)1 site (5%)
Don’t knowN/AN/A2 sites (10%)N/A5 sites (25%)N/A7 sites (35%)
  • IBD, inflammatory bowel disease.